Systematic review: societal cost of illness of inflammatory bowel disease is increasing due to biologics and varies between continents.

IBD societal cost of illness is increasing, driven by growing costs of medication, and varies considerably between continents. While biologic therapy was expected to decrease inpatient costs by reducing hospitalisations and surgery, these costs have not declined.